Carolina Indian Community - CarolinaIndian.com
| | | | | | | | | | | |
 


 

IIT Guwahati, Hester Biosciences collaborate to develop COVID-19 vaccine

Assam,National,Health/Medicine

Author : Indo Asian News Service

Read Latest News and Articles

Share With Your Friends



Add an Article

View All Contributions

Add To My Favorite

Add A Picture

Guwahati, April 29 (IANS) Indian Institute of Technology Guwahati (IIT-G) on Wednesday announced a collaboration with pharmaceutical company Hester Biosciences Limited to develop a vaccine against coronavirus (COVID-19).

The vaccine is expected to be ready by the end of this year for animal studies. The work is currently in its early stage of development, IITG said in a statement.

The vaccine will be based on a recombinant avian paramyxovirus based vector platform. The recombinant avian paramyxovirus-1 will be used to express the immunogenic protein of SARS-CoV-2 virus.

The recombinant avian paramyxovirus-1 expressing the SARS-CoV-2 protein could be used as a vaccine candidate for further study, the Institute said.

"It is too early to comment on the efficacy and immunogenicity of the vaccine, however, we will be able to reveal more details about this vaccine after the results of animal studies are obtained," said researcher Dr Sachin Kumar, Associate Professor, Department of Biosciences and Bioengineering, IIT Guwahati.

According to the Institute, the avian paramyxovirus-1 has been explored as a vaccine vector for various animals and human pathogens.

The avian paramyxovirus-1 has been used to express the immunogenic protein of human pathogens such as HIV, avian influenza virus, human parainfluenza virus, SARS-CoV.

Similarly, it has also been explored as a vaccine vector for animal pathogens such as infectious bursal disease virus, infectious laryngotracheitis virus, bovine herpes virus, Nipah virus etc.

The research team has generated the recombinant avian paramyxovirus-1 based vaccine flatform for classical swine fever and Japanese encephalitis. The role of the Institute is to produce the recombinant vaccine candidate.

"IITG and Hester have collaborated to develop and manufacture a recombinant vaccine against COVID-19 disease as a preventive measure. Hester's involvement would be from master seed development up to release of the commercial vaccine," said Rajiv Gandhi, CEO and MD, Hester Biosciences Limited.

--IANS

bu/na


Copyright and Disclaimer: All news and images appearing in our news section, search engines and social media are provided by IANS. If you face any issues related to the content/images, please contact our news service provider directly. We are not liable/responsible for any content/images related to the news service provider.


Latest News

View More News


More News Articles

How Taha Shah Badussha auditioned for 15 months for his 'Heeramandi' role

To get the honour of leading New Zealand is a huge privilege, says Michael Bracewell ahead of T20Is v Pakistan

Nargis Fakhri as a child dreamt of becoming a vet and not an actor

Sayantani Ghosh opens up on playing a Rajasthani: 'Being Bengali I find it hard to pick up dialects'

Bhojpuri actress Akshara Singh enjoys autorickshaw ride to work